CHINA: Hong Kong’s first-ever Cannabis Investor Symposium will take place on November 1, 2018 at the W Hotel. The one-day gathering is hosted by The Arcview Group, CannaTech and URI Capital Management.
The Cannabis industry is the fastest growing market in the world and the legal cannabis business is expected to generate $57 billion globally by 2027 as countries throughout the world continue to legalize its use and demand continues to grow exponentially.
The Hong Kong Symposium will focus on the global investment opportunity but is specially curated toward the Asian market.
The most powerful cannabis business leaders and investment experts from around the world will gather to discuss the burgeoning industry.
Keynote and panel discussions will cover Cannabis and China, The Cannabis Value Chain, Market Insights: Australasia, Public and Private Investment Opportunities, Risks and Regulations, World Cannabis Policy and more.
The event is designed for those looking to gain insight into investment opportunities in the global cannabis market, family offices, money managers, venture capital firms, private equity funds, and institutional investors.
Troy Dayton, CEO of The Arcview Group adds: “The worldwide cannabis market is exploding, and Asian investors are increasingly paying attention. Up until now, pioneering Asian investors have only been able to simply read about this fascinating industry. Not anymore. We are bringing the cannabis industry to them.”
Saul Kaye, CEO of CannaTech and iCAN said of the symposium, “The time has come for serious Asian investors to enter the market. The Hong Kong event will take place days after CannaTech Sydney, Australia’s first Medical Cannabis Summit. The region’s attitude is evolving quickly, particularly with respect to Medical Cannabis and the industry needs to learn more. Currently dominated by American and Canadian investors, the time is right for the Asian investment community to join this industry. We are thrilled to partner with Arcview and URI Fund on this important event.”
Uri Capital Management added: “Cannabis usage as a medicinal plant dates back in Chinese history for thousands of years. Medicinal cannabis research is rapidly progressing, and we need to redefine our attitude towards cannabis and hemp. Asia, more specifically China, is poised to leverage its unique advantages in Hemp and agriculture to become a dominant global leader. URI is proud to become the first Chinese financial conglomerate to focus on the Asian cannabis industry and will leverage the firm’s world class research and investment resources to lead the way.”
For more information about the Hong Kong Cannabis Symposium, click here.